• DOI:10.1093/ndt/gfs259
• Corpus ID: 19344244

FGF-23: the rise of a novel cardiovascular risk marker in CKD.

@article{Heine2012FGF23TR,
  title={FGF-23: the rise of a novel cardiovascular risk marker in CKD.},
  author={Gunnar Heine and Sarah Seiler and Danilo Fliser},
  journal={Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association},
  year={2012},
  volume={27 8},
  pages={
          3072-81
        }
}

• G. Heine, S. Seiler, D. Fliser
• Published 1 August 2012
• Biology, Medicine
• Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association

Elevated plasma levels of the phosphaturic hormone fibroblast growth factor 23 (FGF-23) are a hallmark of chronic kidney disease (CKD)-mineral and bone disorder. FGF-23 allows serum phosphate levels within physiological limits to be maintained in progressive CKD until end-stage renal disease is reached. Despite its seemingly beneficial role in phosphate homeostasis, several prospective studies in dialysis patients and in patients with less advanced CKD associated elevated FGF-23 with poor cardiovascular and renal outcome. Moreover, very recent evidence suggests an adverse prognostic impact of elevated FGF-23 even in subjects without manifest CKD. These epidemiological data are supplemented by laboratory findings that reveal a pathophysiological role of FGF-23 in the pathogenesis of myocardial injury. In aggregate, these clinical and experimental data identify FGF-23 as a promising target of novel therapeutic interventions in CKD and beyond, which should be tested in future clinical trials.